Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA’s assessment confirms the U.S. supply of these prescription-only GLP-1 medicines now meets or exceeds both current and projected U.S. demand.
All doses of the only real FDA-approved semaglutide medicines are being continuously shipped, meeting or exceeding expected U.S. demand.
FDA’s decision means that making or selling a knockoff compounded drug that is essentially a copy of Ozempic or Wegovy is illegal, under compounding laws, with rare exceptions.
